The galanin-3 receptor antagonist, SNAP 37889, reduces operant responding for ethanol in alcohol-preferring rats

Regulatory Peptides

Volumn 166, Issue 1-3, 2011, Pages 59-67

  Ash, Belinda L ^a   Zanatta, Shannon D ^b   Williams, Spencer J ^b   Lawrence, Andrew J ^c,d   Djouma, Elvan ^a  

^a LA TROBE UNIVERSITY   (Australia)

^b UNIVERSITY OF MELBOURNE   (Australia)

^c FLOREY INSTITUTE OF NEUROSCIENCE AND MENTAL HEALTH   (Australia)

^d UNIVERSITY OF MELBOURNE   (Australia)

Author keywords

Alcohol; Alcohol dependence; Ethanol intake; Galanin; GALR3; Oral self administration

Indexed keywords

ALCOHOL; DRUGS USED IN THE TREATMENT OF ADDICTION; GALANIN RECEPTOR 3; SACCHARIN; SNAP 37889; SUCROSE; UNCLASSIFIED DRUG;

ALCOHOL CONSUMPTION; ALCOHOLISM; ANIMAL EXPERIMENT; ANIMAL MODEL; ANXIETY; ARTICLE; CONTROLLED STUDY; DRINKING BEHAVIOR; DRUG MECHANISM; INSTRUMENTAL CONDITIONING; LIGHT DARK CYCLE; LOCOMOTION; MALE; MAZE TEST; NONHUMAN; PRIORITY JOURNAL; RAT; RECEPTOR BLOCKING; SEDATION;

ALCOHOL DRINKING; ANIMALS; ANXIETY; BEHAVIOR, ANIMAL; CONDITIONING, OPERANT; INDOLES; MALE; RATS; RECEPTOR, GALANIN, TYPE 3; SACCHARIN; SELF ADMINISTRATION; SUCROSE;

RATTUS;

EID: 78650172853     PISSN: 01670115     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.regpep.2010.08.009     Document Type: Article

References (56)

1. Australian Institute of Health and Welfare Statistics on drug use in Australia 2006 2007, AIHW, Canberra.
2. Australian Institute of Health and Welfare 2007 National Drug Strategy Household Survey: detailed findings 2008, AIHW, Canberra.
3. Ministerial Council on Drug Strategy National Alcohol Strategy 2006-2009 2006, Commonwealth of Australia, Canberra.
4. Lewis M.J., Johnson D.F., Waldman D., Leibowitz S.F., Hoebel B.G. Galanin microinjection in the third ventricle increases voluntary ethanol intake. Alcohol Clin Exp Res 2004, 28:1822-1828.
5. Moller C., Sommer W., Thorsell A., Heilig M. Anxiogenic-like action of galanin after intra-amygdala administration in the rat. Neuropsychopharmacol 1999, 21:507-512.
6. Rada P., Avena N.M., Leibowitz S.F., Hoebel B.G. Ethanol intake is increased by injection of galanin in the paraventricular nucleus and reduced by a galanin antagonist. Alcohol 2004, 33:91-97.
7. Karlsson R.M., Holmes A. Galanin as a modulator of anxiety and depression and a therapeutic target for affective disease. Amino Acids 2006, 31:231-239.
8. Lu X., Barr A.M., Bartfai T. Galanin receptors as novel drug targets for the treatment of depression and anxiety. Drug Dev Res 2005, 65:227-236.
9. Holets V.R., Hokfelt T., Rokaeus A., Terenius L., Goldstein M. Locus coeruleus neurons in the rat containing neuropeptide Y, tyrosine hydroxylase or galanin and their efferent projections to the spinal cord, cerebral cortex and hypothalamus. Neuroscience 1988, 24:893-906.
10. Sweerts B.W., Jarrott B., Lawrence A.J. Expression of preprogalanin mRNA following acute and chronic restraint stress in brains of normotensive and hypertensive rats. Brain Res Mol Brain Res 1999, 69:113-123.
11. Branchek T.A., Smith K.E., Gerald C., Walker M.W. Galanin receptor subtypes. Trends Pharmacol Sci 2000, 21:109-117.
12. Robinson J.K., Brewer A. Galanin: a potential role in mesolimbic dopamine-mediated instrumental behavior. Neurosci Biobehav Rev 2008, 32:1485-1493.
13. Mennicken F., Hoffert C., Pelletier M., Ahmad S., O'Donnell D. Restricted distribution of galanin receptor 3 (GalR3) mRNA in the adult rat central nervous system. J Chem Neuroanat 2002, 24:257-268.
14. Waters S.M., Krause J.E. Distribution of galanin-1, -2 and -3 receptor messenger RNAs in central and peripheral rat tissues. Neuroscience 2000, 95:265-271.
15. Barr A.M., Kinney J.W., Hill M.N., Lu X., Biros S., Rebek J., Bartfai T. A novel, systemically active, selective galanin receptor type-3 ligand exhibits antidepressant-like activity in preclinical tests. Neurosci Lett 2006, 405:111-115.
16. Swanson C.J., Blackburn T.P., Zhang X., Zheng K., Xu Z.Q., Hokfelt T., Wolinsky T.D., Konkel M.J., Chen H., Zhong H., Walker M.W., Craig D.A., Gerald C.P., Branchek T.A. Anxiolytic and antidepressant-like profiles of the galanin-3 receptor (Gal3) antagonists SNAP 37889 and SNAP 398299. Proc Natl Acad Sci USA 2005, 102:17489-17494.
17. Lewis M.J., Rada P., Johnson D.F., Avena N.M., Leibowitz S.F., Hoebel B.G. Galanin and alcohol dependence: neurobehavioral research. Neuropeptides 2005, 39:317-321.
18. Koob G.F., Roberts A.J., Schulteis G., Parsons L.H., Heyser C.J., Hyytia P., Merlo-Pich E., Weiss F. Neurocircuitry targets in ethanol reward and dependence. Alcohol Clin Exp Res 1998, 22:3-9.
19. Karatayev O., Baylan J., Weed V., Chang S., Wynick D., Leibowitz S.F. Galanin knockout mice show disturbances in ethanol consumption and expression of hypothalamic peptides that stimulate ethanol intake. Alcohol Clin Exp Res 2010, 34:72-80.
20. Karatayev O., Baylan J., Leibowitz S.F. Increased intake of ethanol and dietary fat in galanin overexpressing mice. Alcohol 2009, 43:571-580.
21. Belfer I., Hipp H., Bollettino A., McKnight C., Evans C., Virkkunen M., Albaugh B., Max M.B., Goldman D., Enoch M.A. Alcoholism is associated with GALR3 but not two other galanin receptor genes. Genes Brain Behav 2007, 6:473-481.
22. Cowen M.S., Djouma E., Lawrence A.J. The metabotropic glutamate 5 receptor antagonist 3-[(2-methyl-1, 3-thiazol-4-yl)ethynyl]-pyridine reduces ethanol self-administration in multiple strains of alcohol-preferring rats and regulates olfactory glutamatergic systems. J Pharmacol Exp Ther 2005, 315:590-600.
23. Lawrence A.J., Cowen M.S., Yang H.J., Chen F., Oldfield B. The orexin system regulates alcohol-seeking in rats. Br J Pharmacol 2006, 148:752-759.
24. Liang T., Spence J., Liu L., Strother W.N., Chang H.W., Ellison J.A., Lumeng L., Li T.K., Foroud T., Carr L.G. alpha-Synuclein maps to a quantitative trait locus for alcohol preference and is differentially expressed in alcohol-preferring and non-preferring rats. Proc Natl Acad Sci USA 2003, 100:4690-4695.
25. Konkel M.J., Packiarajan M., Chen H., Topiwala U.P., Jimenez H., Talisman I.J., Coate H., Walker M.W. Amino substituted analogs of 1-phenyl-3-phenylimino-2-indolones with potent galanin Gal3 receptor binding affinity and improved solubility. Bioorg Med Chem Lett 2006, 16:3950-3954.
26. Liang J.H., Chen F., Krstew E., Cowen M.S., Carroll F.Y., Crawford D., Beart P.M., Lawrence A.J. The GABA(B) receptor allosteric modulator CGP7930, like baclofen, reduces operant self-administration of ethanol in alcohol-preferring rats. Neuropharmacology 2006, 50:632-639.
27. Lodge D.J., Lawrence A.J. The CRF1 receptor antagonist antalarmin reduces volitional ethanol consumption in isolation-reared fawn-hooded rats. Neuroscience 2003, 117:243-247.
28. Cowen M.S., Adams C., Kraehenbuehl T., Vengeliene V., Lawrence A.J. The acute anti-craving effect of acamprosate in alcohol-preferring rats is associated with modulation of the mesolimbic dopamine system. Addict Biol 2005, 10:233-242.
29. Leibowitz S.F., Avena N.M., Chang G.Q., Karatayev O., Chau D.T., Hoebel B.G. Ethanol intake increases galanin mRNA in the hypothalamus and withdrawal decreases it. Physiol Behav 2003, 79:103-111.
30. Lu X., Barr A.M., Kinney J.W., Sanna P., Conti B., Behrens M.M., Bartfai T. A role for galanin in antidepressant actions with a focus on the dorsal raphe nucleus. Proc Natl Acad Sci USA 2005, 102:874-879.
31. Martinetti M.P., Khan Z., Lewis M.J. Matching law choice analyses of ethanol and sucrose consumption in alcohol-preferring (P), nonpreferring (NP), and Sprague-Dawley (SD) rats. Alcohol Clin Exp Res 2007, 31:1338-1348.
32. Bourin M., Hascoet M. The mouse light/dark box test. Eur J Pharmacol 2003, 463:55-65.
33. Lundstrom L., Prinssen E., Kolczewski S., Wettstein J.G., Schuler F., Moreau J.-L., Spooren W., Gatti S., Trube G. Galanin receptor 3 antagonist SNAP 37889: pharmacological characterization and pharmacokinetic profile. The American Society for Pharmacology and Experimental Therapeutics (ASPET) centennial meeting 2008, San Diego, CA.
34. Djouma E., Lawrence A.J., Zanatta S.D., Williams S.J. The galanin-3 antagonist, SNAP 37889, reduces preference for operant-responding of ethanol in alcohol-preferring iP rats. Eur Neuropsychopharmacol 2009, 19:S643.
35. Crawley J.N., Robinson J.K., Langel U., Bartfai T. Galanin receptor antagonists M40 and C7 block galanin-induced feeding. Brain Res 1993, 600:268-272.
36. Corwin R.L., Robinson J.K., Crawley J.N. Galanin antagonists block galanin-induced feeding in the hypothalamus and amygdala of the rat. Eur J Neurosci 1993, 5:1528-1533.
37. Kyrkouli S.E., Strubbe J.H., Scheurink A.J. Galanin in the PVN increases nutrient intake and changes peripheral hormone levels in the rat. Physiol Behav 2006, 89:103-109.
38. Schick R.R., Samsami S., Zimmermann J.P., Eberl T., Endres C., Schusdziarra V., Classen M. Effect of galanin on food intake in rats: involvement of lateral and ventromedial hypothalamic sites. Am J Physiol 1993, 264:R355-R361.
39. Brewer A., Robinson J.K. Galanin stimulation of feeding is blocked by the addition of a response requirement. Behav Neurosci 2008, 122:949-953.
40. Schneider E.R., Rada P., Darby R.D., Leibowitz S.F., Hoebel B.G. Orexigenic peptides and alcohol intake: differential effects of orexin, galanin, and ghrelin. Alcohol Clin Exp Res 2007, 31:1858-1865.
41. Kask K., Berthold M., Bartfai T. Galanin receptors: involvement in feeding, pain, depression and Alzheimer's disease. Life Sci 1997, 60:1523-1533.
42. Koegler F.H., York D.A., Bray G.A. The effects on feeding of galanin and M40 when injected into the nucleus of the solitary tract, the lateral parabrachial nucleus, and the third ventricle. Physiol Behav 1999, 67:259-267.
43. Smith K.E., Walker M.W., Artymyshyn R., Bard J., Borowsky B., Tamm J.A., Yao W.J., Vaysse P.J., Branchek T.A., Gerald C., Jones K.A. Cloned human and rat galanin GALR3 receptors. Pharmacology and activation of G-protein inwardly rectifying K + channels. J Biol Chem 1998, 273:23321-23326.
44. Tsuda K., Yokoo H., Goldstein M. Neuropeptide Y and galanin in norepinephrine release in hypothalamic slices. Hypertension 1989, 14:81-86.
45. Swiergiel A.H., Wieczorek M. Noradrenaline-induced feeding responses in the rat do not depend on food characteristics. Acta Neurobiol Exp 2008, 68:354-361.
46. Swiergiel A.H., Peters G. Injection of noradrenaline into the hypothalamic paraventricular nucleus produces vigorous gnawing in satiated rats. Life Sci 1987, 41:2251-2254.
47. Middaugh L.D., Lee A.M., Bandy A.L. Ethanol reinforcement in nondeprived mice: effects of abstinence and naltrexone. Alcohol Clin Exp Res 2000, 24:1172-1179.
48. Williams K.L., Winger G., Pakarinen E.D., Woods J.H. Naltrexone reduces ethanol- and sucrose-reinforced responding in rhesus monkeys. Psychopharmacology (Berl) 1998, 139:53-61.
49. Williams K.L., Woods J.H. Conditioned effects produced by naltrexone doses that reduce ethanol-reinforced responding in rhesus monkeys. Alcohol Clin Exp Res 1999, 23:708-715.
50. Williams K.L., Pakarinen E.D., Woods J.H. Quadazocine decreases responding reinforced by ethanol, sucrose, and phencyclidine fluid deliveries in rhesus monkeys: comparison to naltrexone's effects. Psychopharmacology (Berl) 1999, 144:316-322.
51. Mark T.L., Kranzler H.R., Song X., Bransberger P., Poole V.H., Crosse S. Physicians' opinions about medications to treat alcoholism. Addiction 2003, 98:617-626.
52. Morris P.L.P., Hopwood M., Whelan G., Gardiner J., Drummond E. Naltrexone for alcohol dependence: a randomized controlled trial. Addiction 2001, 96:1565-1573.
53. Grey C., Osborn E., Reznikoff M. Psychosocial factors in outcome in two opiate addiction treatments. J Clin Psychol 1986, 42:185-189.
54. Hulse G., O'Neil G. Using naltrexone implants in the management of the pregnant heroin user. Aust N Z J Obstet Gynaecol 2002, 42:569-573.
55. Koob G.F., Kenneth Lloyd G., Mason B.J. Development of pharmacotherapies for drug addiction: a Rosetta stone approach. Nat Rev Drug Discov 2009, 8:500-515.
56. Volkow N.D., Wang G.J., Fowler J.S., Telang F. Overlapping neuronal circuits in addiction and obesity: evidence of systems pathology. Philos Trans R Soc Lond B Biol Sci 2008, 363:3191-3200.